UroGen Pharma to Report Third Quarter 2026 Financial Results

PRINCETON, N.J., Oct. 27, 2026 /CourierPR/ -- UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, will report its third quarter 2026 financial results on Wednesday, November 4, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

UroGen Pharma has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. This technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. The company’s first product, aimed at treating low-grade upper tract urothelial cancer, and its second product for adult patients with recurrent low-grade, non-muscle-invasive bladder cancer (LG-IR-NMIBC), are designed to ablate tumors non-surgically. UroGen Pharma is headquartered in Princeton, New Jersey, with operations in Israel. The company’s mission is to provide better treatment options for patients suffering from urothelial and specialty cancers.